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ABSTR ACT
PURPOSE AND METHODS: Our secondary analyses compared survival with eribulin versus capecitabine in various patient subgroups from a phase 3, 
open-label, randomized study. Eligible women aged 18 years with advanced/metastatic breast cancer and 3 prior chemotherapies (2 for advanced/
metastatic disease), including an anthracycline and taxane, were randomized 1:1 to intravenous eribulin mesylate 1.4 mg/m2 on days 1 and 8 or twice-daily 
oral capecitabine 1250 mg/m2 on days 1–14 (21-day cycles).
RESULTS: In the intent-to-treat population (eribulin 554 and capecitabine 548), overall survival appeared longer with eribulin than capecitabine in 
various subgroups, including patients with human epidermal growth factor receptor 2-negative (15.9 versus 13.5 months, respectively), estrogen receptor-
negative (14.4 versus 10.5 months, respectively), and triple-negative (14.4 versus 9.4 months, respectively) disease. Progression-free survival was similar 
between the treatment arms.
CONCLUSIONS: Patients with advanced/metastatic breast cancer and human epidermal growth factor receptor 2-, estrogen receptor-, or triple-negative 
disease may gain particular benefit from eribulin as first-, second-, and third-line chemotherapies.
TRIAL REGISTR ATION (PRIMARY STUDY): This study reports the subgroup analyses of eribulin versus capecitabine from a phase 3, open-label, 
randomized study (www.clinicaltrials.gov; ClinicalTrials.gov identifier: NCT00337103).
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Introduction
Chemotherapy is an integral part of management of patients 
with breast cancer, either alone or in combination with other 
agents. While many chemotherapy options are available for 
patients with pretreated metastatic breast cancer (MBC), their 
optimal sequence is unclear with hitherto limited data from 
randomized trials.1,2 Despite recent advances, the five-year 
survival rate in patients with advanced/MBC is around 25%, 
with over 40,000 patients expected to die from the disease 
in the United States (US) alone in 2015.3 There remains, 
therefore, a major unmet need for effective, well-tolerated 
therapeutic options with a robust evidence base for the treat-
ment of advanced/MBC. 
Eribulin mesylate is a microtubule dynamics inhibitor 
belonging to the halichondrin class of antineoplastic agents.4,5 
Recent preclinical data suggest that eribulin may also have 
effects on vascular remodeling, the reversal of epithelial–
mesenchymal transition, and suppression of cell migration and 
invasion.6,7 Eribulin is approved for the treatment of advanced 
or MBC in patients who have received at least one (European 
Union [EU]) or two (US) prior chemotherapy regimens for 
metastatic disease, including an anthracycline and a taxane 
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in either the adjuvant or the metastatic setting.8,9 Approval 
is based primarily on results from Study 305/EMBRACE, a 
phase 3, randomized study in which eribulin was associated 
with a significant improvement in overall survival (OS) 
compared to the treatment of physician’s choice (13.2 versus 
10.5 months, respectively; hazard ratio [HR]: 0.81 [95% con-
fidence interval (CI): 0.67, 0.96]; P = 0.01) in patients who had 
received two to five prior chemotherapies.10
More recently, Study 301 compared the efficacy and safety of 
eribulin versus capecitabine as first-, second-, or third-line treat-
ment in 1102 women (eribulin 554 and capecitabine 548) with 
locally advanced or MBC who had received prior anthracycline- 
and taxane-based chemotherapies.11 In this study, eribulin 
achieved a numerically longer OS than capecitabine (15.9 versus 
14.5 months, respectively; HR: 0.88 [95% CI: 0.77, 1.00]; 
P = 0.056), but this did not reach the prespecified criteria for sta-
tistical significance (P = 0.037). There was no difference in pro-
gression-free survival (PFS) between eribulin and capecitabine 
(4.1 versus 4.2 months, respectively; HR: 1.08 [95% CI: 0.93, 
1.25]; P = 0.30). The safety profiles of both drugs were manage-
able and consistent with their known side effects.11
Given these findings, practicing oncologists and their 
patients may want to understand whether specific patient 
subgroups could derive greater benefit from eribulin. Here, 
we assess the efficacy of eribulin compared to capecitabine in 
Study 301 across a range of subgroups, including those with 
human epidermal growth factor receptor 2 (HER2)- and 
triple-negative disease status.
Methods and Statistics
Patients. Patient eligibility criteria have been reported 
previously.11 Briefly, these included females (aged 18 years) 
with histologically or cytologically confirmed locally advanced 
or MBC, 3 prior chemotherapy regimens (including 2 for 
advanced and/or metastatic disease), including an anthracy-
cline and a taxane. HER2-targeted therapy was not allowed 
during study treatment.
As part of the original study (Kaufman et al, 201511), all 
patients provided written informed consent and the primary 
study protocol was approved by all relevant review bodies. 
Because these analyses use existing data from the Kaufman pri-
mary study, additional consent was not sought for these analyses. 
The study was conducted in accordance with the Declaration 
of Helsinki, guidelines of the International Conference for 
Harmonization/Good Clinical Practice, and local requirements.
Study design. This was an international, phase 3, open-
label trial (study number E7389-G000-301; clinicalTrials.gov 
identifier: NCT00337103). Patients were stratified by geo-
graphic region (Latin America, Western Europe/Australia, 
Eastern Europe, North America, Asia, or South Africa) and 
HER2 status (positive, negative, or unknown).11 Patients 
were randomized (1:1) to receive eribulin mesylate 1.4 mg/m2 
(equivalent to 1.23 mg/m2 eribulin [expressed as free base]) 
intravenously over two to five minutes on days 1 and 8 or 
capecitabine 1.25 g/m2 orally twice daily on days 1–14, both in 
21-day cycles, until disease progression, unacceptable toxicity, 
or patient/investigator request to discontinue.
Study objectives and subgroup analyses. The coprimary 
endpoints were OS and PFS; the secondary endpoints were objec-
tive response rate, duration of response, one-, two-, and three-year 
survival, and quality of life. These have been reported previously.11
Prespecified analyses were performed based on (i) patient 
demographics, (ii) receptor status, and (iii) disease status.
(i) Patient demographics included analyses based on age 
groups (40, 40 to 65, and 65 years) and geographic 
region of treatment.
(ii) Receptor status analyses were based on the status of 
HER2 (positive, negative, or unknown), estrogen receptor 
(ER; positive, negative, or unknown), hormone receptor 
(positive [ER-positive and/or progesterone receptor (PR)- 
positive], negative [both ER-negative and PR-negative], 
or unknown), and triple-negative (ER-negative, PR-
negative, and HER2-negative) disease.
(iii) Analyses by disease status involved the number of prior 
chemotherapy regimens for advanced/metastatic disease 
(0 and 1); sites of disease (visceral or nonvisceral only); 
number of organs involved (2 and 2); setting of prior 
anthracycline and taxane therapy (both received as adju-
vant therapy versus at least one received as treatment for 
metastatic disease); and patients whose disease was tax-
ane resistant having progressed within 60 days after the 
last dose of the taxane.
A nonprespecified sensitivity analysis was previously 
requested by the EU health technology assessment authority 
based on the ER status and number of organs involved. In view 
of subsequent approval by the European Medicines Agency 
for eribulin in women who have received at least one prior 
line of chemotherapy for advanced/metastatic disease, further 
nonprespecified post hoc analyses were carried out in patients 
treated in this setting. These included analyses by HER2 sta-
tus, ER status, triple-negative breast cancer, number of organs 
involved (2 and 2), presence of visceral disease, and disease 
progression within 60 days of the last dose of taxane.
Statistical analyses. Subgroup analyses were carried out 
using the same general approach (ie, statistical model, missing 
data handling, and censoring rules) as the primary analysis.11 
The HRs of eribulin versus capecitabine for OS and PFS were 
estimated in stratified Cox regression models with HER2 status 
and region as stratification factors. Stratified log-rank tests were 
used to obtain P-values of treatment difference. Kaplan–Meier 
estimates and distribution curves were determined within each 
arm. In the Study 301 primary analyses, alphas of 0.04 and 0.01 
were used for testing the coprimary endpoints of OS and PFS, 
respectively. Results of the subgroup analyses are presented with 
HR and 95% CI with P-values shown for descriptive purposes 
only. No adjustment was made for multiple testing. To assess 
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whether OS and PFS results were consistent across subgroups, 
forest plots of HR with 95% CIs are provided.
Results
Patients. Overall, 1102 patients in the intent-to-treat 
(ITT) population (see Supplementary Fig. 1) were randomly 
assigned to eribulin (n = 554) or capecitabine (n = 548). Base-
line patient demographics and disease characteristics were 
generally well balanced,11 with only modest differences in 
the proportion of patients with ER-positive (46.8% versus 
50.7%) and triple-negative (27.1% versus 24.5%) disease for 
those randomized to eribulin and capecitabine, respectively. 
Overall, 68.5% of patients had HER2-negative disease 
(see Supplementary Table 1).
Prespecified efficacy analyses.
Patient demographics. OS and PFS between the two 
treatment arms were similar across the age groups studied 
(Fig. 1). Comparison by geographic region found similar 
OS in both treatment arms, with the exception of patients 
treated in Latin America who appeared to have longer OS 
with eribulin than capecitabine (15.9 versus 12.0 months; 
P  =  0.03; Fig. 1A); patients treated in Latin America 
received a similar relative dose intensity of eribulin and 
capecitabine (median: 99.1% versus 96.7%, respectively), 
and there were no imbalances in HER2-, ER-, or triple-
negative status.
PFS was similar between the treatment arms, with the 
exception of apparently greater benefit from capecitabine 
Figure 1. Forest plots of (A) Os and (B) PFs by patient demographics.
Note: data based on independent review in the intent-to-treat population.
Abbreviations: Cap, capecitabine; CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; OS; overall survival; PFS, progression-free survival.
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than eribulin in patients treated in Eastern Europe 
(5.0 versus 4.2 months; P  =  0.02; Fig. 1B), which was not 
observed for OS analysis.
Receptor status. OS was longer with eribulin compared 
to capecitabine in patients with HER2-negative (15.9 versus 
13.5 months, respectively; HR: 0.84 [95% CI: 0.71, 0.98]; 
P  =  0.03; Fig. 2A and Supplementary Fig. 2), ER-negative 
(14.4 versus 10.5 months, respectively; HR: 0.78 [95% CI: 
0.63, 0.96]; P = 0.02; Fig. 2A) and triple-negative (14.4 versus 
9.4 months, respectively; HR: 0.70 [95% CI: 0.54, 0.91]; 
P = 0.01; Fig. 2A and Supplementary Fig. 3) disease. PFS was 
similar in these subgroups (Fig. 2B).
Figure 2. Forest plots of (A) Os and (B) PFs by receptor status.
Notes: *this P-value used values of ‘negative vs Others’ for each receptor status. data based on independent review in the intent-to-treat population.
Abbreviations: Cap, capecitabine; CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio or 
hormone receptor; itt, intent-to-treat; Os; overall survival; PFs, progression-free survival.
Eribulin mesylate versus capecitabine 
81Breast CanCer: BasiC and CliniCal researCh 2016:10
Disease status. In total, 882 of 1102 (80.0%) patients in the 
ITT population (eribulin, n = 438/554 [79.1%]; capecitabine, 
n  =  444/548 [81.0%]) had received 1 prior chemotherapy 
regimen for advanced disease. OS (HR: 0.87 [95% CI: 0.75, 
1.01]) and PFS (HR: 1.07 [95% CI: 0.91, 1.26]) between the 
two treatment arms were similar in patients who had received 
no prior chemotherapy for advanced/metastatic disease com-
pared to those who had received 1 prior chemotherapy regi-
mens (Fig. 3).
In the overall patient population, longer OS (P  0.05) 
was also observed with eribulin than capecitabine in patients 
with only nonvisceral disease (27.8 versus 18.3 months), 
Figure 3. Forest plots of (A) Os and (B) PFs by disease status. 
Note: data based on independent review in the intent-to-treat population.
Abbreviations: Cap, capecitabine; CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; OS; overall survival; PFS, progression-free survival.
Twelves et al
82 Breast CanCer: BasiC and CliniCal researCh 2016:10
patients with 2 organs involved (14.8 versus 11.5 months), 
and those who had previously received an anthracycline and/
or a taxane in the metastatic setting (16.1 versus 14.5 months; 
Fig. 3A). No major differences in PFS were observed in these 
subgroups (Fig. 3B).
Nonprespecified efficacy analyses.
ITT population. The potential benefit of eribulin versus 
capecitabine is supported by the sensitivity analysis requested 
by EU regulators using the Cox model adjusted for the number 
of organs involved and ER status (15.9 versus 13.5 months, 
respectively; HR: 0.81 [95% CI: 0.69, 0.95]; P = 0.03).
Sensitivity analyses in patients with 1 prior chemother-
apy regimens in the metastatic setting. Within this group of 
patients, the majority had received eribulin or capecitabine 
as second-line therapy (63.9% and 66.0%, respectively), the 
remainder receiving them in the third-line or later setting. 
OS was similar with eribulin and capecitabine in patients who 
had received 1 prior chemotherapy regimen (16.0 versus 
14.5 months, respectively; HR: 0.87 [95% CI: 0.75, 1.01]; 
P =  0.06; Fig. 4). A sensitivity analysis specifically in these 
patients showed that OS was apparently longer with eribu-
lin compared to capecitabine in several subgroups, including 
those with HER2-negative (15.9 versus 13.4 months; HR: 
0.84 [95% CI: 0.70, 1.00]; P  0.05), ER-negative (15.2 ver-
sus 10.3 months; HR: 0.64 [95% CI: 0.51, 0.82]; P  0.001), 
and triple-negative (15.2 versus 9.2 months; HR: 0.62 [95% 
CI: 0.46, 0.83]; P  0.01; Fig. 4) disease. With the exception 
of patients with ER-negative and triple-negative disease, PFS 
was similar between the treatment arms for most subgroups 
(see Supplementary Table 2).
To allow for the impact on OS of the large treat-
ment effects in patients with ER-negative disease and those 
with 2 organs involved, a further sensitivity analysis was 
conducted, adjusting the statistical model for these effects. 
In these analyses, median OS in the overall population was 
in favor of eribulin compared to capecitabine (16.0 versus 
Figure 4. Forest plot of Os in patients who received eribulin after one or more prior chemotherapy regimens for advanced disease. 
Abbreviations: Cap, capecitabine; CI, confidence interval; HR, hazard ratio; OS, overall survival.
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14.5 months; HR: 0.82 [95% CI: 0.71, 0.95]; P  0.01; see 
Supplementary Fig. 4). Consistent with above findings, 
eribulin appeared to prolong OS than capecitabine in this 
additional sensitivity analysis in several subgroups, includ-
ing those with HER2-, ER-, and triple-negative disease (see 
Supplementary Fig. 4).
Discussion
In light of the observed survival benefit seen in Study 305/
EMBRACE,10 eribulin is recommended by all major guide-
lines for the treatment of patients with advanced/MBC.1,2,12 
As reported previously, eribulin was not statistically superior 
to capecitabine in Study 301 in terms of OS or PFS, although 
a numerical improvement in OS was seen with eribulin com-
pared to capecitabine (P  =  0.056).11 The current analyses 
provide important information on the efficacy of eribulin com-
pared to capecitabine in a number of patient subgroups, espe-
cially those with HER2-, ER-, and triple-negative disease.
In prespecified analyses of well-known prognostic fac-
tors, improvement in OS appeared to be seen in some sub-
groups with eribulin compared to capecitabine. In particular, 
median OS was longer in patients with HER2-, ER-, and 
triple-negative disease receiving eribulin versus capecitabine 
(by 2.4, 3.9, and 5.0 months, respectively; all P    0.05). 
These results are clinically relevant because HER2-negative 
disease is the largest subgroup, comprising almost 85% of 
women with breast cancer;13 in addition, systemic treatment 
options for triple-negative disease are limited to chemother-
apy.14,15 Although capecitabine is active in patients with triple-
negative breast cancer, eribulin appears to represent a more 
effective treatment option for these women, who represented a 
large subgroup of the Study 301 population, and those treated 
in routine clinical practice; further studies are, however, war-
ranted to confirm this finding.
A potential survival advantage was suggested in 
patients with nonvisceral disease and those with 2 organs 
involved receiving eribulin compared to capecitabine (9.5 
and 3.3 months longer OS, respectively; P    0.05). Both 
findings, especially the subgroup of patients with nonvis-
ceral disease where a greater survival advantage was implied, 
merit further investigation in larger trials. Patients from 
Latin America receiving eribulin also appeared to derive 
greater OS benefit compared to capecitabine treatment. Fur-
ther exploration of this subgroup indicated no major differ-
ences between the treatment arms in terms of receptor status 
or dose intensity of study drug; this may, therefore, repre-
sent a chance finding, together with the apparent benefit in 
PFS in patients from Eastern Europe receiving capecitabine.
A small increase in OS (1.5 months) with eribulin ver-
sus capecitabine was observed in patients who had received 1 
prior chemotherapy regimen for advanced/metastatic disease. 
Additional analyses suggested that eribulin prolonged OS 
compared to capecitabine in several subgroups, including those 
with HER2-, ER-, and triple-negative disease. These findings 
provide clinicians and patients with additional evidence 
specific to the patient population now approved in the EU and 
elsewhere (but not in the US) for treatment with eribulin.
Similar to the primary analysis of this study11 and the 
EMBRACE study,10 eribulin consistently had a greater 
impact on OS than PFS. This may, at least in part, be attrib-
utable to the phenotypic changes and/or eribulin-induced 
changes in tumor phenotype and vasculature observed in pre-
clinical models, which may enhance the efficacy of subsequent 
therapies6,7 and improve outcomes. Further translational 
studies are needed to confirm these preclinical findings.
A limitation of these analyses is that all P values must 
be interpreted in the context of the primary analysis for 
Study 301 not achieving statistical significance. All sub-
sequent secondary and subgroup analyses are, therefore, 
essentially exploratory. Accordingly, no adjustment was made 
for multiple testing in the current analyses, and the P values 
are presented for descriptive purposes only; further studies 
would be needed to confirm these results. While the major-
ity of subgroup analyses were prespecified, some were not, 
including the additional sensitivity analyses in patients who 
had received 1 prior chemotherapy for advanced/metastatic 
disease and the use of an adjusted Cox model with added 
covariates. These analyses resulted, however, from interaction 
with the EU regulatory authorities. They are important in the 
absence of data from prospective studies in patient popula-
tions that match the approved indication for eribulin in the 
EU, namely the second-line or later treatment of MBC. In 
that context, these exploratory and retrospective analyses may 
provide clinicians and patients with valuable additional data 
for eribulin relative to capecitabine, especially in women with 
HER2-, hormone receptor-, and triple-negative breast cancer.
Conclusions
In this subgroup analysis, eribulin was an effective therapeu-
tic option for the treatment of patients with advanced/MBC 
and may especially benefit those with HER2-negative, ER-
negative and triple-negative disease. These data in patients 
treated in the first-, second-, and third-line settings support 
eribulin as an active single agent for patients with advanced/
MBC who have received prior chemotherapy, including an 
anthracycline and a taxane.
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